TABLE I.
Relationship between epitope specificity and TNA
| RTA Contact Pointse | ||||||||
|---|---|---|---|---|---|---|---|---|
| mAba | Isotype | b | IC50c | In Vivod | a and A | d and e | D and E | F and G |
| PH12 | IgGl | 9 | 0.08 | 9/10 | – | + | + | – |
| TB12 | IgGl | 42 | 0.11 | 9/10 | – | + | + | – |
| LE4 | IgGl | 37 | 0.3 | 9/11 | – | + | + | – |
| CH1 | IgGl | 95 | >10 | 2/11 | – | – | + | – |
| SWB1 | IgGl | 200 | >10 | 1/5 | – | – | + | – |
| PA1 | IgGl | 9 | 0.07 | 1/11 | – | – | – | + |
| 6C4 | IgGl | 470 | >10 | 2/11 | – | + | – | + |
| WECH1 | IgGl | 370 | 1.7 | 1/11 | + | – | – | + |
| SyH7 | IgGl | 20 | 0.7 | 0/10 | + | – | – | + |
a
Underlines indicate the five new mAbs described in this study, whereas bold indicates passive protection up to day 7.
b
Apparent binding affinities (×10–12 M).
c
Micrograms per milliliter, as determined in Vero cell assay
d
Indicates number of survivors/total number in group.
e
Secondary structures on RTA associated with each mAb’s epitope. As per convention, capital letters refer to α-helices, and lowercase letters refer to β-strands.